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The conversion of mature somatic cells into pluripotent stem cells,
both by nuclear transfer and transductionwith speciﬁc “reprogram-
ming” genes, represents a major advance in regenerative medicine.
Pluripotent stem cell lines can now be generated from an individu-
al’s own cells, facilitating the generation of immunologically accept-
able stem cell-based therapeutics. Many cell types can undergo
nuclear reprogramming, leading to the question of whether the
identity of the reprogrammed cell of origin has a biological conse-
quence. Peripheral blood, containing a mixture of T, B, NK, and my-
eloid cell types, represents one potential source of reprogrammable
cells. In this study, we describe the unique case ofmice derived from
a reprogrammed T cell. These mice have prerearranged T-cell recep-
tor (TCR) genes in all cells. Surprisingly, ≈50% of mice with prerear-
ranged TCR genes develop spontaneous T cell lymphomas, which
originate in the thymus. The lymphomas arise from developing
T cells, and contain activated Notch1, similar to most human and
mouse T-cell acute lymphoblastic lymphomas. Furthermore, lym-
phomagenesis requires the expression of both prerearranged TCRα
and TCRβ genes, indicating a critical role for TCR signaling. Further-
more, inhibitors of multiple branches of TCR signaling suppress
lymphoma growth, implicating TCR signaling as an essential compo-
nent in lymphoma proliferation. The lymphomagenesis in mice de-
rived from a reprogrammed T cell demonstrates the deleterious
consequences of misregulation of the TCR rearrangement and sig-
naling pathways and illustrates one case of cellular reprogramming
where the identity of the cell of origin has profound consequences.
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Advances in nuclear reprogramming of somatic cells have ledto novel methods of creating pluripotent stem cell lines and
represent an important step toward the generation of patient-
speciﬁc, stem cell-based therapies. Reprogramming to pluri-
potency has been achieved by transfer of a somatic cell nucleus into
an enucleated oocyte, and by enforcing the expression of speciﬁc
reprogramming genes in somatic cells (1, 2). These two methods
have been used to reprogram multiple different cell types, in-
cluding ﬁbroblasts, liver cells, pancreatic β cells, neural progenitor
cells, and T and B cells (2–5). Although many cell types can un-
dergo nuclear reprogramming, the underlying differences between
pluripotent stem cell lines derived from distinct somatic cell types
remain largely undetermined.
We have described a line of mice, LN3, which was derived from
a reprogrammed lymphnodeT-cell nucleus (6). InLN3mice, every
somatic cell contains the recombined T-cell receptor (TCR) genes
of the original LN3 donor T cell, whereas normally TCR gene
rearrangement occurs only in T cells during a speciﬁc stage in their
development. We showed that T-cell development in LN3 mice
was altered because of the accelerated expression of the germ-line
LN3 TCRs. Here, we show that LN3 mice harboring functionally
recombined TCR genes undergo T-cell lymphomagenesis.
T-cell acute lymphoblastic lymphomas and leukemias (T-ALL)
represent 10–25% of acute lymphoblastic lymphomas and leuke-
mia (ALL) cases in humans and arise from developing T cells
within the thymus (7). Several genetic abnormalities have been
implicated in the pathogenesis of T-ALL, including transcription
factor genes in the basic helix–loop–helix, Lim domain containing,
and homeobox families, and genes involved in TCR and cytokine
signaling (7, 8). Among the most predominant genetic lesions
are activating mutations within Notch1, which occur in >50% of
cases (9). Notch also plays an essential role in normal thymocyte
development, where it drives both proliferation and differentia-
tion of early progenitors, indicating that overlapping signaling
pathways drive both normal and malignant proliferation of T-
cell progenitors.
The TCR signaling pathway may represent another important
component of lymphomagenesis. The invariant preTCRα gene
(which acts as a surrogate for TCRα during T-cell development)
has been shown to cooperate with Notch signaling to induce
lymphomagenesis in mice (10). More directly, mice transgenic for
components of the TCR have been shown to undergo lympho-
magenesis, including mice that overexpress a TCRα transgene,
mice that overexpress CD3ε, and mice that express truncated
versions of TCRβ (11–13). These ﬁndings suggest that the TCR
signaling pathway can play a role in driving lymphomagenesis and
also bring up the question of whether a completely unmodiﬁed
TCR expressed at normal levels can be oncogenic.
The LN3 mice were originally generated through the transfer of
the nucleus of a mature T cell into an enucleated egg; this reprog-
rammed cell was used to generate an embryonic stem cell line and,
subsequently, the original LN3 mice. The resultant mice were
backcrossed multiple generations to the C57BL/6 strain, with each
generation selected to maintain the productive TCRα and TCRβ
rearrangements (2, 6). The antigen speciﬁcity of the prerearranged
TCR is unknown, but the LN3 receptor isMHCI restricted (6).We
showed that the prerearranged TCR genes were expressed earlier
than their unrearranged counterparts, resulting in abnormal T-cell
development, which was deﬁned by accumulation in the thymus of
a CD4−CD8−CD3+ population and by a hypertrophic thymic en-
vironment (6). During the course of those experiments, we noticed
that many of the LN3 mice developed T-cell lymphomas, impli-
cating the prerecombined TCR genes as potential oncogenes and
demonstrating a unique phenotype associated with pluripotent cell
lines derived from reprogrammed T cells.
Results
Prerearranged TCR Genes Drive Lymphomagenesis. The lymphomas
that develop in LN3 mice are characterized by an enlarged
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thymic mass composed of blasting cells, which are also often
present in the spleen, lymph nodes, and bonemarrow. The surface
phenotypes of the lymphomas are variable, and each lymphoma is
often composed of several phenotypically distinct subpopulations
that resemble sequential stages of thymocyte development, based
on expression of CD4, CD8, and CD25 (Fig. 1A). Each lymphoma
subpopulation also expresses surface CD3, indicating the pres-
ence of a surface TCR (because the surface expression of CD3
and TCR subunits are concomitant) and consistent with the fact
that these cells contain prerearranged TCR genes (Fig. 1A).
Strikingly, we observed that lymphomas only occurred in mice
that carried both the prerearranged TCRα and TCRβ genes
(LN3) and that no lymphomas developed in mice that expressed
only one (LN3α) or the other (LN3β) (Fig. 1B). TCRα and TCRβ
must be coexpressed and pair to form a viable TCR; therefore, the
correlation of their coexpression with lymphomagenesis sug-
gested that expression and signaling of a fully assembled TCR
drove the generation and/or growth of the lymphomas. The lym-
phomagenesis also correlated with the timing of full-length TCR
expression, which began abnormally early during T-cell de-
velopment in LN3αβ mice (Fig. S1 and ref. 6). In addition, the
ability of these two prerearranged and coexpressed TCR genes to
drive lymphomagenesis was maintained in mice multiple gen-
erations removed from the original cloned mice. Because epige-
netic abnormalities in cloned animals are generally repaired upon
passage of DNA through the germ line, we conclude that the
prerearranged TCR genes, rather than epigenetic abnormalities,
drive lymphomagenesis (14–16).
To investigate the role of canonical TCR signaling in the lym-
phomagenesis of LN3 mice, we generated LN3 mice that lacked
both β2M and I-Ab, and therefore lacked classical MHCI/peptide
andMHCII/peptide complexes. In these mice, T-cell development
is largely blocked at the DP stage, consistent with the requirement
of MHCI for positive selection of LN3 thymocytes. Interestingly,
lymphomas still developed in these mice at a similar rate to the
mice that expressed both MHCI and MHCII, indicating that the
development of lymphomas in the LN3 mice required the mature
TCR, but did not require the TCR to interact with classical MHCI
or MHCII molecules (Fig. 1B). It remains unclear whether sig-
naling through the TCR of the LN3 mice drives lymphomagenesis
through a noncanonical ligand or a ligand-independent mecha-
nism. In addition, RAG expression was not required for lympho-
magenesis in LN3mice, because LN3mice crossed to theRAG2−/−
background also developed lymphomas (Fig. 1B). However, in all
mice analyzed, regardless of RAG or MHC deﬁciencies, the
coexpression of both the prerearranged TCRα and TCRβ chains
was required for lymphomagenesis.
Notch Signaling Is Active in Lymphomas of LN3 Mice. The unusual
origin of these lymphomas led us to investigate the pathways that
drive their transformation and proliferation. Notch activation
plays a critical role in T-cell commitment and development and is
a hallmark of T-ALL (9). In T-cell progenitors, Notch signaling is
initiated by binding to delta-like ligands expressed on thymic ep-
ithelial cells, leading to proteolytic cleavage and nuclear transport
of the transcription activating, intracellular domain of Notch (17).
In lymphomas, Notch can become constitutively activated by
mutations that facilitate its proteolytic activation or by mutations
that increase the stability of the cleaved, activated form (18). The
activated form of Notch1 can be detected by an antibody that
recognizes its free cleaved end, enabling the determination of
Notch1 activation within cell populations (19). To investigate
whether this pathway is activated in the LN3 lymphomas, we
performed Western blots on cell lysates of several primary lym-
phomas by using an antibody speciﬁc for the cleaved, activated
form of Notch1. We found that 15 of 17 primary lymphomas had
activated Notch1 as detected by Western blot, including lympho-
mas that lacked either RAG or MHC molecules. Twelve of the
lymphomas expressed an activated formofNotch1whichmigrated
at the expected molecular weight of the activated, wild type pro-
tein, but 3 lymphomas expressed truncated forms of activated
Notch1, showing that LN3 lymphomas, like human T-ALL, ab-
errantly activate Notch1 genes through multiple molecular
mechanisms. These results indicate that activation of the Notch
pathway represents one of the common hits that drive lympho-
magenesis in LN3 mice.
Activation of TCR-Signaling Components Drives Lymphoma Growth.
In addition to Notch activation, lymphomagenesis in LN3 mice
requires functional prerearranged TCR genes, leading us to in-
vestigate the importance of TCR signaling in lymphoma pro-
liferation. One major downstream transcriptional effector of
TCR activation is the nuclear factor of activated T cells (NFAT),
which translocates to the nucleus after stimulation of the TCR,
and is essential for both T-cell development and T-cell activation
(20). To determine whether NFAT is localized to the nucleus in
A
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Fig. 1. LN3 lymphomas are located in lymphoid organs and have an
immature thymocyte phenotype. (A) Surface phenotype of non-
leukemic (Left) and three separate leukemic thymuses stained for
molecules normally associated with T-cell development, indicating
that the individual lymphomas have heterogeneous phenotypes that
partially overlap with several stages of immature thymocyte de-
velopment. (B) Offspring from a cross of wt × LN3 mice were ana-
lyzed over a 7-mo period for onset of lymphoma. Mice that showed
signs of illness were euthanized, and lymphomas were veriﬁed by
dissection as greatly enlarged thymuses, spleens and/or lymph nodes.
Lymphomas were veriﬁed by ﬂow cytometry. LN3 mice contain both
prerearranged TCRα and TCRβ; LN3α contain only the prerearranged
TCRα; LN3β contain only the prerearranged TCRβ; wt indicates lit-
termates that lacked prerearranged TCR loci; LN3 β2m−/−mice do not
express surface MHCI molecules; LN3 I-Ab−/− mice lack MHCII mole-
cules; and LN3 RAG−/− mice are RAG2-deﬁcient. In all crosses studied,
only mice that expressed both the prerearranged TCRα and TCRβ
chains developed lymphomas. Statistical P values were calculated by
using Fisher’s exact test.
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LN3 lymphomas, we transduced an LN3 lymphoma cell line that
had adapted to culture with an NFAT-eGFP fusion protein that
reproduces the localization of the native protein (21). In these
cells, we observed a stable and low level of NFAT-eGFP ﬂuo-
rescence both in the nucleus and the cytoplasm, evident as
a diffuse green staining throughout the cells (Fig. 2B). This
partial nuclear localization of NFAT-eGFP in untreated cells
contrasts to the state of the cells upon acute activation of the
TCR-signaling pathway by incubation with the pharmacological
agents, phorbol myristate acetate (PMA), and ionomycin (22).
Rapidly after PMA/ionomycin stimulation, the NFAT-eGFP be-
comes almost entirely localized to the nucleus of the lymphoma
cells, and is absent from the periphery and near the plasma
membrane (Fig. 2B). In contrast, treatment of the lymphoma
cells with the calcineurin inhibitor, cyclosporin A (20), caused
the rapid exclusion of NFAT from the nucleus, revealing that
LN3 lymphomas have chronically activated the NFAT-signaling
pathway, possibly through TCR activation (Fig. 2B).
To determine whether NFAT signaling was biologically im-
portant in lymphoma cell growth, we measured the effect of
cyclosporin A on the proliferation of four independent LN3 lym-
phoma lines. We found that low concentrations of cyclosporin A
inhibited growth of each lymphoma line over a 3-d culture period
(Fig. 3B). The susceptibility of the lymphomas to cyclosporin A
indicated that NFAT activation plays an important role in the
proliferation of LN3 lymphomas and suggested that signaling
molecules upstream of NFAT, such as the TCR, might be medi-
ating lymphoma proliferation.
Inhibitors of TCR and Notch Signaling Block Lymphoma Growth. To
test whether more proximal mediators of TCR signaling were also
activated in the LN3 lymphomas, we tested the sensitivity of the
cells to inhibitors of two kinases that are associated with the TCR
synapse, LCK and PKCθ. LCK is associated with CD4, and LCK-
mediated phosphorylation of the ITAMs of the TCR-associated,
CD3 complex is an essential, and very rapid, event downstream of
TCR engagement (23). In parallel, PKCθ is an essential compo-
nent of TCR-mediated T-cell activation and colocalizes with the
TCR synapse (24). We found that inhibitors of both of these
kinases speciﬁcally suppressed LN3 lymphoma growth, whereas
they had no effect on the growth of a B-cell hybridoma line (Fig. 3
C and D). The fact that both of these kinases are required for
proliferation of the LN3 lymphomas strongly implicates TCR
activation as a critical component of LN3 lymphoma proliferation.
Given the parallels between the LN3 lymphomas and human
T-ALL, these data suggest that inhibitors of NFAT activation,
such as cyclosporin A, as well as novel inhibitors of PKCθ, such as
CG0471, which is used here, might also effectively inhibit the
growth of human T-ALL. Notably, cyclosporin A has been shown
to induce apoptosis of human T-ALL cells in culture (25, 26).
Because we had observed that the Notch pathway was active in
these lymphomas, we tested the ability of the lymphomas to grow
in the presence of an inhibitor of gamma secretase, which is the
activating protease of Notch (27). We found that this inhibitor
suppress growth of all of the lymphoma lines tested and also had
no effect on the growth of a B-cell hybridoma at two different
concentrations (Fig. 3A). Notch activation in LN3 lymphomas is
reminiscent of human T-ALL, for which constitutive activation
of Notch is also a common trait (9). Notably, the cell line that
was least sensitive to the gamma secretase inhibitor (RAGLN3
#64) was derived from a primary lymphoma that did not show
activated Notch by Western blot (Figs. 2A and 3A). This same
cell line was also the most sensitive to inhibition of the TCR
signaling pathway, suggesting that the TCR signaling pathway
can act independently of Notch to drive lymphoma growth.
Discussion
Implications for Induced Pluripotent Stem (IPS) Cells.Although many
different cell types can be reprogrammed into pluripotent cell
lines, the biological properties of reprogrammed cells that are
determined by the cell type of origin have remained unclear. In this
study, we show that mice that are several generations removed
from a clone derived from a T-cell nucleus retain the tendency
to undergo lymphomagenesis. This lymphomagenesis required
speciﬁc prerearranged TCRα and TCRβ genes, indicating that
the tendency toward lymphomagenesis was due to the T-cell
origin of the original clone and, speciﬁcally, the expression of
prerearranged TCR genes. It is unclear at this point whether
lymphomagenesis is a general phenomenon of mice with pre-
rearranged TCR genes, but given that TCR transgenic mice can
also develop spontaneous lymphomas, TCR-mediated lympho-
magenesis may be common in mice with misregulated TCR ex-
pression (11). Current methods of reprogramming often begin
with cellular sources such as cord blood, bone marrow, and pe-
ripheral blood: all tissues that contain complex mixtures of cell
types, including T cells. This study suggests that precautions should
be taken to ensure that the identity of the reprogrammed cell of
origin is known, and that T cells, and probably also B cells, are not
inadvertently turned into therapeutic IPS cells. Recent studies
have used human blood-derived T cells as sources of IPS cells, and
these cells promise to be valuable tools for studying human im-
mune development and disease; however, the results presented
here indicate that extra caution is warranted regarding the thera-
peutic use of such T cell-derived IPS cells (28–30).
Implications for Gene Therapy. Transfer of tumor-speciﬁc TCR
genes into hematopoietic stem and progenitor cells has been used
to establish antitumor immunity in mice (31). Our observations in
the LN3 mice suggest that this approach might predispose the
transduced progenitors toward lymphomas. Furthermore, our
previous analysis of LN3 mice showed that developing T cells that
express the prerearranged TCR genes developed very inefﬁciently
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Fig. 2. LN3 lymphomas have activated Notch and NFAT signaling pathways.
(A) Western blots were performed on cell lysates from 17 individual LN3
lymphomas, using an antibody that recognizes the activated (cleaved) form
of Notch. Fifteen of 17 LN3 lymphomas stained positive for the cleaved form
of Notch1 (indicated by arrow), showing that this pathway is activated in the
majority of lymphomas derived from LN3 mice, regardless of RAG expression
(RAG−/−) or β2M and IAb expression (MHC−/−). (B) NFAT-eGFP is partially
nuclear localized in untreated lymphoma cells. Two independent LN3αβ
lymphoma-derived cell lines (LN3A and LN3B) were transduced with a ret-
rovirus encoding an NFAT-eGFP fusion protein. Representative data are
shown from one of these lines (LN3B). Cells were either left untreated, or
treated in culture for 30 min with PMA (1 μM) + ionomycin (250 ng/mL) or
cyclosporin A (10 μM), and then plated onto glass slides with coverslips and
immediately analyzed for on a ﬂuorescence microscope. Untreated cells
have a partially nuclear localized NFAT-eGFP, as compared to cells that have
almost entirely nuclear NFAT-eGFP (PMA/ionomycin treated) and cells that
have almost entirely cytoplasmic NFAT-eGFP (cyclosporin A treated).
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in the presence of wild-type cells (6). This aberrant and lympho-
magenic development of LN3 thymocytes likely stems from the
early expression of the TCR. These observations suggest that fu-
ture approaches that use TCR gene transduction into hemato-
poietic stem cells will beneﬁt from using promoters that drive TCR
expression atmore appropriate (later) time points in development.
Implications for Lymphomagenesis. The occurrence of lymphomas
in the LN3 mice is reminiscent of the lymphomagenesis that has
been reported in HY TCR transgenic mice (11). In those mice, it
was possible that the lymphomagenesis was due to a transgenic
insertion site that activated an oncogene; however, in the LN3
strain, the prerearranged TCR genes are in the normal locus
and, therefore, these results deﬁnitively show that prerearranged
TCR genes can drive lymphomagenesis.
The mechanism that enables prerearranged TCR genes to drive
lymphomagenesis is unclear. The lymphoma proliferation requires
activation of TCR signaling components, including LCK, PKCθ,
and NFATc1, implying that either an activating mutation has oc-
curred within the TCR-signaling pathway or that the TCR is being
ligated by an unidentiﬁed factor. It remains possible that consti-
tutive activation of the TCR signaling pathway spontaneously
arose during the culture adaptation of the lines used in this study.
Although this possibility has not been excluded here, the essential
role of the prerearranged TCR in the initiation of the LN3 lym-
phomas in vivo implicates TCR signaling in the origin of the
lymphomas. The involvement of cell surface mitogenic recep-
tors such as the TCR in leukemogenesis has precedent: Moloney
virus-induced thymic lymphomas in BALB/c and other susceptible
strains can express cell-surface receptors speciﬁc for the inducing
retrovirus, creating a mitogenic loop (32–35). In that model, thy-
mic T-cell clones that bind intact retrovirus self-select for infection
and mitogenic expansion; the expanding cells could derive sub-
clones that activate other protooncogenic events and/or inhibit
tumor suppressors (36). During natural development of thymic
lymphomas in the highly lymphoma-susceptible AKR mouse, the
viruses that emerge to bind the lymphomas are always recombi-
nant between integrated proviruses in the envelope (env) region,
presenting new “antigenic” surfaces to the host (33, 37). In the
AKR mouse, between 25 and 50 wk of life, the virus-binding sub-
population expands; in a preview of the cancer stem cell hypothesis
(38), only the virus-binding T cells transfer the lymphoma to syn-
geneic mice, whereas their coexisting nonbinding T cells are
nonleukemogenic (33, 37). In one such case, the binding of a leu-
kemogenic retrovirus to its cognate leukemia cell line could be
inhibited by antibodies to either CD4 or TCR, implicating the
TCR as the leukemogenic receptor (39). Similarly, virus-binding
surface Ig can play a mitogenic role in viral-mediated B cell leu-
kemogenesis in mice and humans (40, 41). Also, in Friend leuke-
mia virus-induced erythroleukemias, the retroviral env product
appears to bind the erythropoietin receptor on these cells (42).
In the case of the LN3 mice, the TCR is required for both ini-
tiation and ongoing proliferation of lymphomas. Interestingly, this
TCR-mediated lymphomagenesis occurs even in the absence of
a classical ligand, because MHCI−/− II−/− LN3 mice undergo
lymphomagenesis at the same rates as the MHC-expressing LN3
mice. TheTCR-dependent,MHC-independent lymphomagenesis
of LN3 mice suggests that either a nonclassical ligand drives the
LN3 lymphoma to proliferate or, alternatively, that the TCR is
chronically activated in the absence of ligation, possibly by proxi-
mal activating mutations in the signaling pathway. A viral-medi-
ated transformation that activates the TCR signaling pathway also
remains possible.
Targeting the TCR signaling pathway might be a productive
strategy for inhibiting growth of lymphomas, because cyclosporin
A has been shown to kill human lymphoma cells in vitro and
murine lymphoma cells in vivo (25, 26). Previous studies of mice
transgenic for activated Notch showed that signaling through the
pre-TCR is necessary for lymphomagenesis (43). Similarly, the
present study shows that misregulated TCR signaling alone can
be a ﬁrst step in leukemogenesis and such lymphomas use the
TCR signaling pathway for proliferation.
Methods
Mice. The LN3mice have been described (6). They originated from the nuclear
transfer of a lymph node T cell from a 129/SvJae × C57BL/6 F1malemouse into
an enucleated oocyte. The original clones were bred more than six gen-
erations to the C57BL/6 background, with genotyping to maintain the pre-
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Fig. 3. Inhibitors ofNotch1activation,NFAT signaling, LCK, andPKCθall block LN3 lymphomaproliferation. Four independent LN3 lymphomacell lines: RAGLN3
#64 (white bars), RAGLN3 #31 (light gray bars), LN3 A (dark gray bars), LN3 B (black bars), and one B cell hybridoma (dotted bars, as a control for nonspeciﬁc
toxicity) were plated at 5,000 cells per well andwere treated with a γ-secretase inhibitor (A), cyclosporin A (B), an Lck inhibitor (C), or a PKCθ inhibitor (D). Three
days later, live cells were counted byﬂow cytometry, and percent growthwas calculated as: 100 × (number of cells in treatedwell) / (number of cells in untreated
wells). Results are representative of at least four independent experiments for each inhibitor and each cell line. A titration of inhibitors were used in each assay,
and concentrations that did not affect B cell hybridoma growth were chosen where possible to ensure that the inhibitors were not acting through nonspeciﬁc
toxicity (this control for toxicity was not possible for cyclosporin A, which is known to also inhibit B-cell lymphoma growth).
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rearranged TCR genes. RAG2−/−, β2M−/−, and I-Ab−/− mice, all on the C57BL/6
background, were originally obtained from JAX Labs (Bar Harbor, ME). Mice
were housed in the Stanford University Medical Center, and the Stanford
Animal Use and Care Committee approved all experiments involving animals.
Cell Lines and Culture. Four LN3 lymphoma cell lines were derived from in-
dependent mice. These lines were derived by disaggregation of lymphomic
thymuses into single cells, and culture of cells in IMDM + 10% FCS in the
presence of 10 ng/mL interleukin 7. These cultures typically slowly died off,
and then rare cells proliferated and gave rise to immortalized cell lines, which
were IL-7 independent. An antibody-producing B cell hybridoma, PC.61, was
used as a non-T-cell lymphoma control for the inhibitor experiments.
Inhibitors of γ-secretase (γ-secretase IX), Lck (PP2), and NFAT (cyclosporin A)
were purchased from Calbiochem. The PKCθ speciﬁc inhibitor, CG0471, was
identiﬁed from a chemical library at Complegen and has an IC50 of 0.1 μM
for PKCθ, 1.2 μM for PKCδ, 0.9 μM for PKCε, and 0.1 μM for PKCη.
NFAT-eGFP and Microscopy. Two independent LN3 lymphoma lines were
infected with a retrovirus encoding NFAT-eGFP (a generous gift of Andrew
T. Girvin). Transduced GFP+ cells were sorted by FACS and cultured for fur-
ther experiments. Cells were treated with phorbol 12-myristate 13-acetate
(250 ng/mL) and ionomycin (1 μM), or with cyclosporin A (10 μM), or left
untreated for 30 min at 37 °C, and were then immediately placed on slides
and were analyzed on a Nikon Eclipse E800 microscope equipped with
a mercury lamp and a ﬂuorescent ﬁlter for GFP.
Antibodies, Flow Cytometry, and Cell Sorting. Flow cytometry and cell sorting
was performed either on a FACSaria equipped with 405-, 488-, and 633-nm
lasers or on a highly modiﬁed Benton Dickinson FACSmachine by using argon
405-, 488-, and 598-nm lasers, and data were collected by using DIVA digital
electronics. Analysis of data was performed with FlowJo (TreeStar). Live cells
were gated based on forward and side scatter and propidium iodide ex-
clusion. Antibodies to CD3ε (KT31.1), CD4 (GK1.4), CD8 (53-6.7), and CD25
(PC61) were either purchased directly conjugated to phycoerythrin (PE),
Cy7PE, or Cy5PE (BD Pharmingen) or were puriﬁed from hybridoma super-
natants and directly conjugated to ﬂuorochromes Paciﬁc blue, Paciﬁc or-
ange, Alexaﬂuor 488, or Alexaﬂuor 647 (Molecular Probes).
Western Blots. Cells were lysed in 1%Triton X-100 in PBS on ice in the presence
of protease inhibitor mixture III (Calbiochem). Lysates were cleared by cen-
trifugation at 14,000 × g for 15 min, and the equivalent of 100,000 cells were
separated on an 8% SDS/PAGE gel and blotted onto PVDF (Amersham). Blots
were blocked with 10% BSA fraction V, or with 5% nonfat milk, in 0.05%
Tween 20, 150 mM NaCl, 20 mM Tris at pH 7.5, and then rabbit antibody to
activated Notch 1 (Cell Signaling) was added at a ﬁnal concentration of
1:2,000. Blots were washed extensively and then incubated with 1:5,000
dilution of goat anti-rabbit horseradish peroxidase (Invitrogen). Blots were
developed by using a bioluminescent substrate (Amersham), and light-sen-
sitive ﬁlm (Kodak).
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